(VIANEWS) – AMSC (AMSC.OL), SELVAAG BOLIG (SBO.OL), FRANCAISE ENERGIE (FDE.PA) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. AMSC (AMSC.OL)
1395% sales growth and 8.21% return on equity
AMSC ASA, through its subsidiaries, operates as a ship owning and lease finance company in the United States. The company purchases and bareboat charters out vessels to operators and end users. It operates a fleet of nine product tankers, one shuttle tanker, and one subsea construction vessel. The company was formerly known as American Shipping Company ASA and changed its name to AMSC ASA in October 2022. AMSC ASA was founded in 2005 and is headquartered in Lysaker, Norway.
Earnings Per Share
As for profitability, AMSC has a trailing twelve months EPS of kr2.12.
PE Ratio
AMSC has a trailing twelve months price to earnings ratio of 10.61. Meaning, the purchaser of the share is investing kr10.61 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.21%.
Sales Growth
AMSC’s sales growth is 1367.3% for the present quarter and 1395% for the next.
Revenue Growth
Year-on-year quarterly revenue growth grew by 39.6%, now sitting on 102.25M for the twelve trailing months.
Moving Average
AMSC’s worth is way below its 50-day moving average of kr39.16 and way below its 200-day moving average of kr41.54.
More news about AMSC.
2. SELVAAG BOLIG (SBO.OL)
133% sales growth and 10.32% return on equity
Selvaag Bolig ASA, a housing development company, engages in the development, construction, and sale of residential properties in Greater Oslo, Bergen, Stavanger, Trondheim, and Stockholm. The company also offers project management services. Selvaag Bolig ASA was incorporated in 2008 and is headquartered in Oslo, Norway. Selvaag Bolig ASA is a subsidiary of Selvaag AS.
Earnings Per Share
As for profitability, SELVAAG BOLIG has a trailing twelve months EPS of kr2.58.
PE Ratio
SELVAAG BOLIG has a trailing twelve months price to earnings ratio of 10.16. Meaning, the purchaser of the share is investing kr10.16 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.32%.
Revenue Growth
Year-on-year quarterly revenue growth declined by 13.4%, now sitting on 3.14B for the twelve trailing months.
Volume
Today’s last reported volume for SELVAAG BOLIG is 32587 which is 35.42% below its average volume of 50465.
Sales Growth
SELVAAG BOLIG’s sales growth is negative 58.1% for the current quarter and 133% for the next.
Earnings Before Interest, Taxes, Depreciation, and Amortization
SELVAAG BOLIG’s EBITDA is 66.02.
More news about SELVAAG BOLIG.
3. FRANCAISE ENERGIE (FDE.PA)
50% sales growth and 17.3% return on equity
La Française de l'Energie S.A., a carbon-negative energy producer, focuses on energy recovery and production sites for reducing greenhouse gas emissions in France. The company supplies CO2, gas, electricity, and heat. It has an installed capacity of 7.5 megawatts in Wallonia. La Française de l'Energie S.A. was incorporated in 2007 and is headquartered in Faulquemont, France.
Earnings Per Share
As for profitability, FRANCAISE ENERGIE has a trailing twelve months EPS of €2.94.
PE Ratio
FRANCAISE ENERGIE has a trailing twelve months price to earnings ratio of 14.44. Meaning, the purchaser of the share is investing €14.44 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.3%.
Moving Average
FRANCAISE ENERGIE’s worth is higher than its 50-day moving average of €41.81 and higher than its 200-day moving average of €41.78.
More news about FRANCAISE ENERGIE.
4. NAVAMEDIC (NAVA.OL)
17.3% sales growth and 10.19% return on equity
Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Northern Europe. The company's product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. It offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic acidemia/propionic acidemia, glutaric aciduria, isovaleric acidemia, and urea cycle disorders, as well as products for glycogen storage diseases and renal diseases, fat metabolism, malnutrition, and ketogenic diet. In addition, the company provides consumer health products consisting of non-prescription drugs and health care products for pain relief, cough and cold, gastro, obesity, women's health, and others primarily through pharmacies and drugstores; specialty pharmaceutical products in various therapeutic areas comprising dermatology, wound care, urology, and obesity; and branded generics, including cardiology products and antibiotics. It sells, markets, and distributes its products to hospitals, patients, and pharmacies. The company was formerly known as Glucomed AS and changed its name to Navamedic ASA in 2004. Navamedic ASA was incorporated in 2002 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, NAVAMEDIC has a trailing twelve months EPS of kr1.18.
PE Ratio
NAVAMEDIC has a trailing twelve months price to earnings ratio of 31.69. Meaning, the purchaser of the share is investing kr31.69 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.19%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 12.3%, now sitting on 454.46M for the twelve trailing months.
Moving Average
NAVAMEDIC’s worth is above its 50-day moving average of kr36.13 and higher than its 200-day moving average of kr36.95.
More news about NAVAMEDIC.
5. DNB BANK (DNB.OL)
12% sales growth and 15.02% return on equity
DNB Bank ASA provides financial services for retail and corporate customers in Norway and internationally. The company offers personal banking products and services, including savings and investment products; loans, such as home mortgages, and car and consumer loans; pet, home and property, travel, and personal insurance products, as well as insurance products for vehicles; retirement savings products; foreign exchange and treasury activities; and Internet and mobile banking services, as well as cards. It also provides business banking products and services comprising savings and investment products consisting of savings accounts, fixed rate deposits, exchange traded products, bonds and commercial papers, asset management, and equity services; financing, such as installment loans, overdraft facility, bank guarantees, leasing, factoring, and trade and export financing services; transaction banking services; research, commodities, bonds and commercial papers, corporate finance, debt capital market, equities, foreign exchange and interest rates, and securities services; and Internet services, including online equity trading, online FX trading, e-confirmation, equities execution, and investor and margin accounts, as well as pension services. In addition, the company provides investment banking services, such as mergers and acquisition, and equity and debt capital market services; foreign exchange, interest rates, equities, commodities, fixed income, research, private equity, and securities services; and corporate banking services. Further, it offers private banking services. The company offers its products and services to various sectors, including energy; financial institutions; healthcare; manufacturing; packaging and forest products; seafood; shipping, offshore, and logistics; and telecom, media, and technology. DNB Bank ASA was founded in 1822 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, DNB BANK has a trailing twelve months EPS of kr24.81.
PE Ratio
DNB BANK has a trailing twelve months price to earnings ratio of 8.14. Meaning, the purchaser of the share is investing kr8.14 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.02%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 16.6%, now sitting on 74.07B for the twelve trailing months.
Sales Growth
DNB BANK’s sales growth is 24.3% for the present quarter and 12% for the next.
Moving Average
DNB BANK’s value is under its 50-day moving average of kr202.30 and higher than its 200-day moving average of kr193.35.
More news about DNB BANK.
6. SKUE SPAREBANK (SKUE.OL)
11.9% sales growth and 9.5% return on equity
Skue Sparebank provides various banking products and services for individual and business in Norway. The company offers operating, tax deduction, capital, client, deposit, and group accounts; business, construction, personal, vehicle, and small loans, as well as mortgage, bank guarantee, overdraft, and leasing services; and home and leisure, car and other vehicles, pet, company and employees, agriculture insurance products. It also provides savings and pension products; and online and mobile banking, bank card, and payment services. The company was formerly known as Nes Prestegjelds Sparebank and changed its name to Skue Sparebank in October 2013. Skue Sparebank was founded in 1842 and is based in Geilo, Norway.
Earnings Per Share
As for profitability, SKUE SPAREBANK has a trailing twelve months EPS of kr85.05.
PE Ratio
SKUE SPAREBANK has a trailing twelve months price to earnings ratio of 2.59. Meaning, the purchaser of the share is investing kr2.59 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.5%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 31.5% and 29.2%, respectively.
Yearly Top and Bottom Value
SKUE SPAREBANK’s stock is valued at kr220.00 at 22:20 EST, way under its 52-week high of kr246.00 and way higher than its 52-week low of kr198.00.
Sales Growth
SKUE SPAREBANK’s sales growth for the next quarter is 11.9%.
More news about SKUE SPAREBANK.
7. SPAREBANKEN ØST (SPOG.OL)
11.3% sales growth and 7.72% return on equity
Sparebanken Øst operates as a savings bank in Eastern Norway. The company offers financial products, such as savings, credit, and payment products; current accounts; home mortgage loans; and mortgage loans for new and used cars. It also provides vehicles, houses and contents, boats, and leisure insurance products, as well as life and health insurance products; and shares and funds trading services. In addition, the company buys, sells, and stores cryptocurrencies, as well as operates, manages, leases, and sells real estate properties. The company was founded in 1843 and is headquartered in Drammen, Norway.
Earnings Per Share
As for profitability, SPAREBANKEN ØST has a trailing twelve months EPS of kr5.61.
PE Ratio
SPAREBANKEN ØST has a trailing twelve months price to earnings ratio of 8.41. Meaning, the purchaser of the share is investing kr8.41 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.72%.
More news about SPAREBANKEN ØST.
8. VISTIN PHARMA (VISTN.OL)
6.6% sales growth and 5.32% return on equity
Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, produces and sells active pharmaceutical ingredients (APIs) worldwide. It offers metformin HCl APIs and direct compressive granulates for the pharmaceutical industry. The company was founded in 1969 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, VISTIN PHARMA has a trailing twelve months EPS of kr1.
PE Ratio
VISTIN PHARMA has a trailing twelve months price to earnings ratio of 23. Meaning, the purchaser of the share is investing kr23 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.32%.
More news about VISTIN PHARMA.
